Accuray (Nasdaq:ARAY) and Limbus AI announced today that they are partnering to augment Accuray’s adaptive radiotherapy capabilities.
The partnership aims to leverage Limbus’ artificial intelligence (AI)-driven auto contouring algorithms to enable a streamlined treatment planning process.
Sunnyvale, California-based Accuray and Saskatchewan, Canada-based Limbus AI anticipate an integrated offering will be made available beginning in 2023, according to a news release.
Limbus AI’s contouring algorithms help to define the border of the tumor and organs at risk during radiation therapy, completing what the companies described as one of the most critical steps in the planning process. That step accounts for a significant proportion of both the personnel and time involved in plan adaptation, too.
The automation of the contouring portion of the planning process also allows for practical adaptive plan modification, when warranted, without overwhelming a stretched clinical staff, the companies said. Limbus added that automation tools like its AI for contouring make it easier for medical teams to ensure consistency in the plans created.
Accuray CEO Joshua H. Levine said in the release that the partnership allows for personalized patient care with the company’s Synchrony AI-driven, real-time target tracking with dynamic delivery technology on both the Radixact and CyberKnife systems.
“We’re thrilled to be working closely with the Accuray team to bring our AI models directly to the treatment machine, where accuracy and efficiency are critical to providing the best patient care. Both companies are focused on providing the best tools to clinicians to enhance radiotherapy treatment delivery,” Limbus AI CEO and Medical Director Dr. Joshua Giambattista said in the release. “We are confident that our AI models will continue to set the standard for automatic contouring for all treatment plans, including those used in adaptive therapy. This technology will improve efficiency for clinicians, enabling optimal treatment planning in a shorter period of time. These advances will expand the utilization of treatment machines so more patients can receive state of the art care.”
